Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).


Clinical Trial Description

The trial will consist of a single visit, in which the following procedures will be carried out: - Demographic data. - Clinical history. - Inclusion/exclusion criteria. - General examination. - Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control). - Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed. - Evaluation of adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05532566
Study type Interventional
Source Inmunotek S.L.
Contact Miguel Casanovas
Phone 912908942
Email mcasanovas@inmunotek.com
Status Not yet recruiting
Phase N/A
Start date January 2, 2023
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04058743 - Nickel Sensitivity N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Active, not recruiting NCT05605795 - Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Completed NCT04510376 - Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method N/A
Completed NCT05185479 - Analysis of Adverse Events in Anesthesia Using Artificial Intelligence
Recruiting NCT05185362 - Epidemiology of Pecan Nut Allergy
Completed NCT03525496 - Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents
Completed NCT03489694 - Repeatability and Reproducibility of Skin Test Endpoint Titration
Completed NCT03942692 - What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
Enrolling by invitation NCT05670756 - Preoperative Survey to Evaluate Patient Allergy
Recruiting NCT05462444 - Development of Personalized Balanced Nutrition Concept Through an IT Platform
Not yet recruiting NCT05284253 - Is There an Allergy to Pure Metallic Gold Microparticles? N/A
Completed NCT03157505 - Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis Phase 3
Completed NCT01436617 - Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab Phase 2
Not yet recruiting NCT05533385 - Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. N/A
Recruiting NCT06011603 - Prineo Sensitivity Dressing Study Phase 4
Completed NCT04761822 - COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations Phase 2
Recruiting NCT05367531 - Assessment of Injectable Medication Platforms N/A